Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Total Liabilities (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Total Liabilities for 6 consecutive years, with $54.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Liabilities fell 41.96% to $54.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $54.3 million, a 41.96% decrease, with the full-year FY2025 number at $54.3 million, down 41.96% from a year prior.
  • Total Liabilities was $54.3 million for Q4 2025 at Relay Therapeutics, down from $62.3 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $168.9 million in Q3 2022 to a low of $38.6 million in Q1 2021.
  • A 5-year average of $101.9 million and a median of $95.8 million in 2021 define the central range for Total Liabilities.
  • Biggest YoY gain for Total Liabilities was 202.81% in 2021; the steepest drop was 83.28% in 2021.
  • Relay Therapeutics' Total Liabilities stood at $110.6 million in 2021, then soared by 35.18% to $149.6 million in 2022, then plummeted by 38.5% to $92.0 million in 2023, then rose by 1.66% to $93.5 million in 2024, then plummeted by 41.96% to $54.3 million in 2025.
  • Per Business Quant, the three most recent readings for RLAY's Total Liabilities are $54.3 million (Q4 2025), $62.3 million (Q3 2025), and $63.2 million (Q2 2025).